| 13.55 -0.4 (-2.87%) | 08-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.83 | 1-year : | 18.25 |
| Resists | First : | 14.41 | Second : | 15.62 |
| Pivot price | 13.73  |
|||
| Supports | First : | 12.44 | Second : | 10.35 |
| MAs | MA(5) : | 14.05  |
MA(20) : | 13.52 |
| MA(100) : | 16.76 |
MA(250) : | 19.22 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.2 |
D(3) : | 47.5 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 45 | Low : | 10.48 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LYEL ] has closed above bottom band by 42.4%. Bollinger Bands are 50.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.05 - 14.13 | 14.13 - 14.2 |
| Low: | 13.35 - 13.45 | 13.45 - 13.54 |
| Close: | 13.8 - 13.95 | 13.95 - 14.09 |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Fri, 14 Aug 2026
Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership - Stock Titan
Thu, 13 Aug 2026
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Tue, 11 Aug 2026
Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes - Stock Titan
Tue, 11 Aug 2026
Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding - Stock Titan
Tue, 11 Aug 2026
Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL - marketbeat.com
Sat, 08 Aug 2026
Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -77 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.451e+007 (%) |
| Held by Institutions | 1.035e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 31000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -12.69 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 213 % |
| Return on Equity (ttm) | 50 % |
| Qtrly Rev. Growth | -80.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7604e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.07 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.22e+006 |
| Forward Dividend | 1.32e+006 |
| Dividend Yield | 9003690% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|